Nieuw onderzoek over Q10 en carnitine

Je kan je via dit forum aan de anderen voorstellen en discusieren over hart en vaatziekten.
Willy
Verslaafd aan het forum
Berichten: 13314
Lid geworden op: di okt 09, 2001 3:00 am
Locatie: Exloo
Contacteer:

Nieuw onderzoek over Q10 en carnitine

Bericht door Willy » do mei 11, 2017 12:26 pm

CARNITINE EN HARTFALEN

L-carnitine in the secondary prevention of cardiovascular disease: systematic review and meta-analysis

CONCLUSION: Compared with placebo or control, L-carnitine is associated with a 27% reduction in all-cause mortality, a 65% reduction in VAs, and a 40% reduction in anginal symptoms in patients experiencing an acute myocardial infarction. Further study with large randomized controlled trials of this inexpensive and safe therapy in the modern era is warranted.

https://www.ncbi.nlm.nih.gov/pubmed/23597877

Q10 EN HARTFALEN

Effect of coenzyme Q₁₀ supplementation on heart failure: a meta-analysis.

Pooled analyses of available randomized controlled trials suggest that CoQ₁₀ may improve the EF in patients with CHF. Additional well-designed studies that include more diverse populations are needed.

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3742297/

Treatment of congestive heart failure with coenzyme Q10 illuminated by meta-analyses of clinical trials

In conclusion, supplemental treatment of CHF with CoQ10 is consistent with an improvement of SV, EF, CO, CI and EDVI. Homogeneity could be established for SV and CO. Additional clinical trials of the effect of CoQ10 on CHF are necessary, but, on the basis of the evidence currently available, the possibility remains that CoQ10 will receive a well-documented role as an adjunctive treatment of CHF

https://www.ncbi.nlm.nih.gov/pubmed/9266518

OVERZICHT BELANGRIJKE VITAMINES BIJ HARTFALEN

Micronutrients in chronic heart failure

Heart failure (HF)-associated mortality remains high, despite guideline-recommended medical therapies. Poor nutritional status and unintentional cachexia have been shown to have a strong association with worse survival in HF patients. Importantly, micronutrient deficiencies are potential contributing factors to the progression of HF. This review aims to summarize contemporary evidence on the role of micronutrients in the pathophysiology and outcome of HF patients. Emphasis will be given to the most well-studied micronutrients, specifically, vitamin D, vitamin B complex, coenzyme Q10 and L-carnitine.

https://www.ncbi.nlm.nih.gov/pubmed/23070580

Nutritional assessment in heart failure patients

Amino acids such as taurine, which is involved in calcium exchange, has been reported to improve heart function. Coenzyme Q10, a key component in the electron transport chain, is vital for energy production. l-carnitine, an amino acid derivative, is responsible for transport of fatty acids into the mitochondria along with modulating glucose metabolism. Thiamine and the other B vitamins, which serve as vital cofactors, can often be deficient in HF patients. Omega-3 fatty acid supplementation has been demonstrated to benefit HF patients potentially through anti-arrhythmic and anti-inflammatory mechanisms. Vitamin D supplementation can potentially benefit HF patients by way of modulating the renin-angiotensin system, smooth muscle proliferation, inflammation, and calcium homeostasis.

https://www.ncbi.nlm.nih.gov/pubmed/21790970

CARNIINE BIJ BEHANDELING HARTFALEN BIJ KINDEREN DOOR CHEMO

Carnitine and cardiac dysfunction in childhood cancer survivors treated with anthracyclines

Childhood cancer survivors are at high risk of developing congestive heart failure (CHF) compared with the general population, and there is a dose-dependent increase in CHF risk by anthracycline dose.
After adjusting for multiple comparisons, individuals with cardiac dysfunction had significantly lower plasma carnitine levels [relative ratio (RR), 0.89; P < 0.01] in relation to those with normal systolic function. These findings may facilitate the development of primary prevention (treatment of carnitine deficiency before/during anthracycline administration) and secondary prevention strategies (screening and treatment in long-term survivors) in patients at highest risk for CHF. Cancer Epidemiol Biomarkers

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4053243/

Q10 BIJ DE BEHANDELING VAN KINDEREN MET HARTFALEN

Coenzyme Q10 improves diastolic function in children with idiopathic dilated cardiomyopathy.

Our results, therefore, indicate that administration of coenzyme Q10 is useful in ameliorating cardiac failure in patients with idiopathic dilated cardiomyopathy through its significant effect on improving diastolic function.

https://www.ncbi.nlm.nih.gov/pubmed/19703336

The effect of coenzyme Q10 on idiopathic chronic dilated cardiomyopathy in children

CoQ10 may improve NYHA class and CT ratio and shorten ventricular depolarization in children with chronic idiopathic DCM.

https://www.ncbi.nlm.nih.gov/pubmed/16374685

Potential role of ubiquinone (coenzyme Q10) in pediatric cardiomyopathy

Coenzyme Q10 is a vitamin-like nutrient that has a fundamental role in mitochondrial function, especially as it relates to the production of energy (ATP) and also as an antioxidant. Based upon the biochemical rationale and a large body of data on patients with adult cardiomyopathy, heart failure, and mitochondrial diseases with heart involvement, a role for coenzyme Q10 therapy in PCM patients is indicated, and preliminary results are promising.

https://www.ncbi.nlm.nih.gov/pubmed/15896419
Met vriendelijke groeten,

Willy Witsel

Ben je blij met ons gratis advies doe dan
een tweet of een like bovenin deze forumpagina

Plaats reactie